title: Transient hyperopia after intensive treatment of hyperglycemia in newly diagnosed diabetes.
abstract: OBJECTIVE
  Our aim was to observe the transient hyperopia during the intense glucose reduction in patients with newly diagnosed diabetes and severe hyperglycemia.
  
  
  METHODS
  Consecutive cases were observed.
  
  
  RESULTS
  Totally 4 men and 1 woman with a mean age of 48 years were enrolled. In the 4 patients who received insulin, the hyperopia developed at 4.2 days after the initiation of treatment on average and reached a peak at 11.7 days; they recovered at 64.0 days. The other subject who received oral hypoglycemia agents revealed a peak change at 17 days and recovered at 70 days. A broader hyperopic change of 6.25 dpt was found in the patient with high myopia (-16 dpt). No significant difference was observed in the corneal curvature, axial length, lens thickness or depth of the anterior chamber during the course. The stable value of the accommodation amplitude and lens thickness may indicate that the cause of refraction change was due to the alteration in the reflection index of the lens.
  
  
  CONCLUSIONS
  Intensive glucose reduction may cause transient hyperopia changes in newly diabetic patients and results in blurred vision.
authors.affiliation: Department of Ophthalmology, Buddhist Tzu-Chi General Hospital, Hualien, Taiwan, ROC.
authors.forename: Shu-Fang
authors.initials: SF
authors.lastname: Lin
authors.forename: Po-Kang
authors.initials: PK
authors.lastname: Lin
authors.forename: Fang-Ling
authors.initials: FL
authors.lastname: Chang
authors.forename: Rong-Kung
authors.initials: RK
authors.lastname: Tsai
mesh_terms: D000284:Administration, Oral; D000328:Adult; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy* / Q000503:physiopathology; D006956:Hyperopia / Q000139:chemically induced* / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D007328:Insulin / Q000009:adverse effects; D007908:Lens, Crystalline / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D020127:Recovery of Function; D012029:Refraction, Ocular / Q000187:drug effects; D012720:Severity of Illness Index; D013997:Time Factors; D014786:Vision Disorders / Q000139:chemically induced / Q000503:physiopathology
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin